Health Optimization Index
Full-Spectrum Hemp (CBD)
- Nick’s assessment
- Promising
- Research evidence
- C, mixed evidence
- Attention
- 4.7 / 100▼ Falling this week
BioHarmony score
Full-spectrum hemp extract delivers cannabidiol (CBD), the only cannabis compound with an FDA-approved drug (Epidiolex, 2018). Purified CBD cut convulsive seizures in Dravet syndrome by 39% versus 13% on placebo per Devinsky 2017. Consumer-wellness uses are weaker, and 70% of online products were mislabeled per Bonn-Miller 2017.
Read the full report Benefits, risks and practical guidance.
Read Nick’s assessment Why it earned this rating
Full-spectrum hemp is a 6.5–7.0/10, worth-trying intervention for people who want a low-dependency, well-tolerated option and who keep their expectations matched to the evidence. The practical verdict is to treat it as proven for narrow neurological and acute-anxiety uses and unproven-but-low-risk for everything else. Who should consider it: anyone managing situational anxiety, or a caregiver navigating a diagnosed seizure disorder under a neurologist. Who should be cautious: people on interacting prescriptions and anyone expecting it to fix sleep, chronic pain, or recovery on the strength of the marketing. The tier is justified because a benign safety and dependency profile lifts it above heavily-marketed drugs, while the proven-versus-hyped gap and real liver and drug-interaction caveats keep it below the strong-recommend band. Sourcing caveat: because only 31% of products were accurately labeled per Bonn-Miller 2017, buy only third-party-tested product with a matching certificate of analysis.
✅ Best for: Adults with situational or social anxiety who want a non-intoxicating, non-dependence-forming option and will use higher acute doses near the studied range. Caregivers and patients managing Dravet or Lennox-Gastaut seizures under neurology supervision, where the evidence is strongest. People who want a low-friction daily supplement to trial against one defined outcome and stop if there is no signal by four weeks. Those who dislike the dependence and tolerance issues of conventional anti-anxiety or sleep drugs and want a gentler alternative to test. Experienced supplement users who will pay for third-party-tested product and read the certificate of analysis.
❌ Avoid if: You take clobazam, valproate, warfarin, or other narrow-therapeutic-index drugs without clinician review, because CBD inhibits CYP3A4 and CYP2C19 and can raise their levels. You have existing liver disease or plan high-dose, long-term use without liver-enzyme monitoring, given the dose-dependent ALT elevations. You need to pass a drug test, since full-spectrum products contain trace THC. You are pregnant or breastfeeding, where safety is not established. You expect proven relief for chronic pain, insomnia, or athletic recovery, where the human evidence is weak or equivocal and better-supported options exist.
Share your experience
Your answers are optional and help other readers — they never change my score. How community input works.
One step left: confirm it’s you
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.
Make a 12-month prediction Will it rise or fall in the Index?
Choose a direction and your confidence. Correct predictions earn leaderboard points.
Your prediction is final once submitted. We’ll check it in 12 months. See the leaderboard →